J
Jay Reddy
Researcher at University of Texas MD Anderson Cancer Center
Publications - 122
Citations - 1927
Jay Reddy is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Radiation therapy & Experimental autoimmune encephalomyelitis. The author has an hindex of 21, co-authored 114 publications receiving 1482 citations. Previous affiliations of Jay Reddy include University of Nebraska–Lincoln & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function
Sheng Xiao,Nader Najafian,Jay Reddy,Monica J. Albin,Chen Zhu,Eric R. Jensen,Jaime Imitola,Thomas Korn,Ana C. Anderson,Zheng Zhang,Cristina Gutierrez,Thomas Moll,Raymond A. Sobel,Dale T. Umetsu,Hideo Yagita,Hisaya Akiba,Terry B. Strom,Mohamed H. Sayegh,Rosemarie H. DeKruyff,Samia J. Khoury,Vijay K. Kuchroo +20 more
TL;DR: T cell immunoglobulin mucin (Tim)-1 regulates T cell responses and that Tim-1 engagement can alter T cell function depending on the affinity/avidity with which it is engaged, as well as two antibodies that showed opposite functional effects.
Journal ArticleDOI
Cutting Edge: CD4+CD25+ Regulatory T Cells Contribute to Gender Differences in Susceptibility to Experimental Autoimmune Encephalomyelitis
Jay Reddy,Hanspeter Waldner,Xingmin Zhang,Zsolt Illes,Kai W. Wucherpfennig,Raymond A. Sobel,Vijay K. Kuchroo +6 more
TL;DR: The authors showed that depletion of Treg cells in male B10.S mice before immunization with PLP 139-151 rendered them highly susceptible to severe EAE with more CNS neutrophil infiltrates than nondepleted controls.
Journal ArticleDOI
Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma
Chelsea C. Pinnix,Grace L. Smith,Sarah A. Milgrom,Eleanor M. Osborne,Jay Reddy,Mani Akhtari,Valerie Klairisa Reed,Isidora Arzu,Pamela K. Allen,Christine F. Wogan,Michele A. Fanale,Yasuhiro Oki,Francesco Turturro,Jorge E. Romaguera,Luis Fayad,Nathan Fowler,Jason R. Westin,Loretta J. Nastoupil,Fredrick B. Hagemeister,M. Alma Rodriguez,Sairah Ahmed,Yago Nieto,Bouthaina S. Dabaja +22 more
TL;DR: In using IMRT to treat mediastinal lymphoma, all dosimetric parameters predicted RP, although small doses to large volumes of lung had the greatest influence.
Journal ArticleDOI
Intensity modulated proton therapy (IMPT) – The future of IMRT for head and neck cancer
Amy C. Moreno,Steven J. Frank,Adam S. Garden,David I. Rosenthal,Clifton D. Fuller,Gary Brandon Gunn,Jay Reddy,William H. Morrison,Tyler D. Williamson,Emma B. Holliday,Jack Phan,Pierre Blanchard +11 more
TL;DR: A systematic approach towards utilizing IMPT and additional prospective studies are necessary in order to more accurately estimate the clinical benefit of IMPT over IMRT and passive proton therapy on a case-by-case basis for patients with sub-site specific HNCs.
Journal ArticleDOI
Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation
Mani Akhtari,Mani Akhtari,Sarah A. Milgrom,Chelsea C. Pinnix,Jay Reddy,Wenli Dong,Grace L. Smith,Osama Mawlawi,Zeinab Abou Yehia,Jillian R. Gunther,Eleanor M. Osborne,T.Y. Andraos,Christine F. Wogan,Eric M. Rohren,Naveen Garg,Hubert H. Chuang,Joseph D. Khoury,Yasuhiro Oki,Michelle A. Fanale,Bouthaina S. Dabaja +19 more
TL;DR: 3-dimensional measurements of disease burden obtained from baseline 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) scans, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), would more accurately risk-stratify patients are tested.